Natalizumab treatment in multiple sclerosis: The experience of S. Andrea MS Centre in Rome

Neurological Sciences

Volumn 31, Issue SUPPL. 3, 2010, Pages

  Prosperini, L ^a   Borriello, G ^a   Fubelli, F ^a   Marinelli, F ^a   Pozzilli, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Multiple sclerosis; Natalizumab; Post marketing study

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; ITALY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; ROME; TREATMENT OUTCOME;

EID: 79960368676     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0348-8     Document Type: Conference Paper

References (17)

1. Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrins. Nature 356:63-66
2. Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
3. Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 8:254-260
4. Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Engl J Med 354:911-923
5. Hartung HP (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8:28-31
6. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
7. Kurtzke JF (1993) Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452
8. Miller DH, Albert PS, Barkhof F et al (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis US National MS Society Task Force. Ann Neurol 39:6-16 (Pubitemid 26052212)
9. http://www.biogenidec.com/site/tysabri-information-center.html (last accessed on 22 March 2010)
10. Oturai AB, Koch-Henriksen N, Petersen T et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16:420-423
11. Putzki N, Yaldizli O, Mäurer M et al (2009) Efficacy of natalizumab in second-line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17:31-37
12. Outteryck O, Ongagna JC, Zéphir H et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257:207-211
13. Hutchinson M, Kappos L, Calabresi PA et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256:405-415
14. Calabresi PA, Giovannoni G, Confavreux C et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391-1403 (Pubitemid 47511460)
15. Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431-441 (Pubitemid 46551850)
16. Dorsey ER, Thompson JP, Noyes K et al (2007) Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 68:1524-1528 (Pubitemid 46685924)
17. Tedeschi G, Amato MP, D'Alessando R et al (2009) The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci 30(Suppl 2):S163-S165